Phase I, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
The purpose of this phase I study is to evaluate the safety and tolerability of HBI-2376 in patients with advanced solid tumors, including pancreatic cancer harboring KRAS or EGFR mutations.
Study ID: HBI-2376-101
Trial Phase: Phase I
Trial Sponsor: HUYABIO International, LLC.
Therapies Used in This Trial: HBI- 2376